Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.
Zacks Investment Research on MSN2d
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & MoreBayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm ...
"In people with lupus nephritis, Gazyva/Gazyvaro demonstrated a complete renal response benefit, a meaningful clinical ...
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA) for ...
In a new study, researchers investigated microRNA-203 as a potential biomarker for lupus nephritis (LN) and found that ...
The US regulator has started a review of Roche's supplemental biologics license application (BLA) for Gazyva/Gazyvaro ...
For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...
Submission is supported by positive results from the Phase III REGENCY trial, which demonstrated that nearly half of patients ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback